PharVision Advisers’s ITT ITT Stock Holding History

PharVision Advisers’s Portfolio ITT Stock Details ITT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,644	Closed	-$285K	–	376
2025 Q4	$285K	Buy	+1,644	New	+$295K	0.14%	299
2025 Q3	–	Sell	-1,747	Closed	-$274K	–	725
2025 Q2	$274K	Buy	+1,747	New	+$249K	0.39%	101

Other funds holding ITT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

PharVision Advisers's ITT Position: Q1 2026 in Review

PharVision Advisers sold out of ITT (ITT) in Q1 2026, closing a stake of 1,644 shares — an estimated $285K sold.

PharVision Advisers first reported a position in ITT in Q2 2025 and held it in 2 quarters. The position peaked at $285K in Q4 2025. 715 funds tracked by Wall St. Rank hold ITT as of Q1 2026.

PharVision Advisers reported no remaining ITT position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 1,644 ITT shares in Q1 2026, an estimated $285K.
PharVision Advisers first reported a position in ITT in Q2 2025 and held it in 2 quarters.
PharVision Advisers's ITT position peaked at $285K in Q4 2025.
715 funds tracked by Wall St. Rank held ITT as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.